The active metabolite of prasugrel effectively blocks the platelet P2Y<sub>12</sub>receptor and inhibits procoagulant and pro-inflammatory platelet responses
Heather M. Judge(Royal Hallamshire Hospital), Robert F. Storey(University of Sheffield), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Robert Buckland(Umeå University), Joseph A. Jakubowski(Indiana Biosciences Research Institute)
Cited by 62
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Complete Revascularization with Multivessel PCI for Myocardial Infarction
|New England Journal of Medicine|2019|926